全球思覺失調症流行病學分析與預測：2026 年

預計到 2026 年，全球思覺失調症患者人數將達到 125 萬，到 2031 年將達到 133 萬，年複合成長率為 0.7%。

人們對精神疾病的認知不斷提高、診斷能力的提升、醫療保健服務的普及以及流行病學監測的加強，都促進了全球對精神疾病認知的進步，思覺失調症揭示疾病的盛行率、發病率、已確診和未確診患者人數、人口分佈、疾病嚴重程度、死亡率趨勢、區域疾病負擔以及未來流行病學預測。了解這些趨勢對於醫療保健規劃、藥物研發、臨床試驗患者招募以及公共衛生政策制定至關重要。流行病學研究表明，思覺失調症是導致嚴重精神疾病致殘的主要原因之一，其盛行率的上升主要歸因於人口成長和存活率的提高，而非年齡標準化盛行率的顯著增加。

思覺失調症是一種慢性精神障礙，其特徵是幻覺、妄想、認知障礙、情緒失調和社會功能障礙。它通常始於青春期晚期或成年早期，許多患者需要終身接受臨床治療。儘管思覺失調症在全球人口中所佔比例相對較小，但其造成的慢性損害、生活品質下降以及醫療資源利用率增加，仍會對患者、看護者、醫療系統和國家經濟產生顯著的長期影響。

精神病診斷技術的進步、標準化臨床指南的製定、神經影像學研究的開展、數位醫療技術的進步以及公眾對心理健康意識提升，都有助於更早診斷和更好地監測疾病。各國政府和醫療機構也努力擴大心理健康項目，加強社區精神科服務，並改善病患獲得專科醫療服務的途徑。這些努力有望提高診斷率，並減少治療啟動的延誤。

對流行病學研究、數位化患者登記、人工智慧診斷和真實世界資料收集的投入不斷增加，正在加深我們對不同人群疾病模式的理解。流行病學情報的改進正在幫助製藥公司設計有針對性的臨床試驗、最佳化商業策略並開發個人化治療方案。隨著精神健康在醫療保健系統中持續受到重視，預計在預測期內，思覺失調症的診斷患者人數將穩定成長。

市場促進因素

人們對心理健康的認知不斷提高

提高公眾意識的宣傳活動、減少社會歧視以及改善醫學教育，正在加速思覺失調症的早期發現和診斷。

提高公眾意識有望改善患者識別和治療途徑。

擴大心理健康護理服務

世界各國政府繼續投資精神病院、社區心理健康中心、遠距精神科和綜合行為醫學。

改善醫療保健服務有助於早期診斷和長期疾病管理。

診斷技術的進步

神經影像學、生物標記研究、數位化評估和標準化精神病學評估工具的進步正在提高診斷準確性。

這些技術也有助於改善早期療育和病患監測。

流行病學研究的擴展

大規模患者登記、人口健康資料庫和縱向研究的擴展，加深了我們對思覺失調症的盛行率、發病率和疾病進展的了解。

流行病學數據的豐富有助於制定醫療計劃和開發治療方法。

增加精準精神醫學的投資

遺傳學、生物標記和個人化醫療方面的研究正在推動患者分層，並支持更個人化的治療策略。

精準精神病學有望為未來的流行病學分析和臨床結果的改善做出貢獻。

本報告對全球思覺失調症市場進行了流行病學概述，總結了該疾病和治療概況、受影響患者人數、新患者、確診患者和接受治療患者人數的趨勢和預測，按治療類型、年齡層、性別和嚴重程度進行了詳細分析，分析了區域和主要國家的趨勢、相關政策和法規、競爭格局、主要公司概況以及未來展望。

目錄

第1章執行摘要

第2章：思覺失調症：概述

• 疾病概述
• 病因和危險因子
• 疾病的病理生理學
  • 多巴胺失調
  • 麩胺酸功能障礙
  • GABA能通路
  • 神經發炎和免疫機制
  • 突觸可塑性的變化
• 疾病負擔及其對醫療保健的影響
  • 殘障負擔
  • 死亡與平均壽命
  • 對生活品質的影響
  • 經濟負擔
  • 看護者的負擔

第3章：流行病學調查方法與預測框架

• 流行病學模型的結構
• 資料來源和檢驗框架
• 患者數量建模的前提條件
• 預測方法
• 疾病定義和病例識別標準
• 評估診斷率的框架
• 評估治療滲透率的框架
• 敏感度分析和情景分析

第4章：全球思覺失調症流行病學概述

• 全球患病人數
  • 對過去趨勢的分析
  • 預測分析
• 全球新患者數
  • 既往發病率趨勢
  • 預測未來疾病發生率趨勢
• 確診患者人數
  • 確診患者人數
  • 未確診患者人數
• 接受治療的患者人數
  • 按治療類型分類的患者數
  • 未治療的疾病負擔
• 按年齡層別分類的疾病負擔
  • 兒童和青少年
  • 青年人
  • 成人
  • 老年人
• 性傳染病負擔
  • 男性
  • 女士
• 按嚴重程度分類的疾病負擔
  • 輕症
  • 緩和
  • 嚴重

第5章 按疾病階段和臨床特徵分類的流行病學

• 首發思覺失調症
• 早思覺失調症
• 慢性思覺失調症
• 難治性思覺失調症
• 思覺失調症
• 以陰性症狀為主的患者群
• 認知障礙患者群
• 合併症負擔評估

第6章：醫療保健和治療狀況的流行病學

• 已確診患者及未確診患者
• 接受治療的患者和未接受治療的患者
• 獲得精神科護理的機會
• 獲得抗精神病藥物治療
• 獲得長效注射劑（LAI）療法
• 對精神衛生保健基礎設施的影響
• 報銷和保險覆蓋範圍對診斷的影響

第7章 流行病學趨勢和導致疾病負擔的因素

• 人口成長的影響
• 老化的影響
• 都市化趨勢
• 心理健康意識提升活動
• 醫療基礎設施擴建
• 診斷能力的提升
• 社會經濟因素
• 數位心理健康整合
• 早期療育計畫的影響
• 公共衛生政策的影響

第8章：預測分析與流行病學預測

• 全球流行病學預測
  • 患病患者總數預測
  • 預測新患者總數
  • 預計確診患者人數
  • 預測需要治療的患者人數
• 按年齡層進行的預測
• 性別預測
• 基於嚴重程度的預測
• 依疾病階段進行預測
• 基於治療狀態的預測
• 不同情境下的預測

第9章 區域分析

• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲

第10章：主要國家分析

• 加拿大
• 德國
• 中國
• 日本
• 印度

第11章 比較流行病學評價

• 按地區比較疾病負擔
• 各國疾病負擔比較
• 發病率比較
• 患病率比較
• 診斷差距比較
• 治療差距比較
• 醫療保健服務獲取情況比較
• 預測成長率比較
• 高疾病負擔國家排名
• 新興成長市場

第12章 醫療保健系統與政策概述

• 全球心理健康政策
• 思覺失調症管理框架
• 篩檢和早期檢測工作
• 醫療保健服務改善計劃
• 贖回環境
• 精神健康領域的資金趨勢
• 意識提升計劃
• 未來政策趨勢

第13章：未來展望與策略洞察

• 到2045年的主要流行病學變化
• 人口和地區疾病負擔日益加重
• 診斷率趨勢
• 治療覆蓋率趨勢
• 擴大心理健康政策的影響
• 引入數位心理健康護理的影響
• 長期疾病負擔展望
• 相關利益者的策略機遇
• 主要風險和不確定性

第14章附錄

The global Schizophrenia prevelance is projected to grow from USD 1.25 million patients in 2026 at a CAGR of 0.7% to USD 1.33 million patients in 2031.

The global schizophrenia epidemiology landscape continues to evolve as increasing awareness of mental health disorders, improved diagnostic capabilities, expanded healthcare access, and strengthened epidemiological surveillance contribute to better disease identification worldwide. Epidemiology analysis provides comprehensive insights into disease prevalence, incidence, diagnosed and undiagnosed patient populations, demographic distribution, disease severity, mortality trends, regional burden, and future epidemiological forecasts. Understanding these trends is essential for healthcare planning, pharmaceutical development, clinical trial recruitment, and public health policy formulation. Epidemiological studies indicate that schizophrenia remains one of the leading causes of disability among severe mental disorders, with prevalence increasing primarily due to population growth and improved survival rather than a significant rise in age-standardized rates.

Schizophrenia is a chronic psychiatric disorder characterized by hallucinations, delusions, cognitive dysfunction, emotional disturbances, and impaired social functioning. The disorder typically develops during late adolescence or early adulthood and requires lifelong clinical management in many patients. Although schizophrenia affects a relatively small proportion of the global population, its long-term impact on patients, caregivers, healthcare systems, and national economies remains substantial because of chronic disability, reduced quality of life, and increased healthcare utilization.

Advancements in psychiatric diagnostics, standardized clinical guidelines, neuroimaging research, digital health technologies, and improved mental health awareness have contributed to earlier diagnosis and better disease monitoring. Governments and healthcare organizations are also expanding mental health programs, strengthening community-based psychiatric services, and improving access to specialist care. These initiatives are expected to increase diagnosis rates while reducing delays in treatment initiation.

Growing investments in epidemiological research, digital patient registries, artificial intelligence-assisted diagnostics, and real-world data collection are enhancing understanding of disease patterns across different populations. Improved epidemiological intelligence is supporting pharmaceutical companies in designing targeted clinical trials, optimizing commercial strategies, and developing personalized therapeutic approaches. As healthcare systems continue prioritizing mental health, the diagnosed schizophrenia population is expected to increase steadily throughout the forecast period.

Market Drivers

Increasing Mental Health Awareness

Growing public awareness campaigns, reduced social stigma, and improved physician education are encouraging earlier recognition and diagnosis of schizophrenia.

Greater awareness is expected to improve patient identification and access to treatment.

Expansion of Mental Healthcare Services

Governments continue investing in psychiatric hospitals, community mental health centers, telepsychiatry, and integrated behavioral healthcare.

Improved healthcare access supports earlier diagnosis and long-term disease management.

Advances in Diagnostic Technologies

Progress in neuroimaging, biomarker research, digital assessments, and standardized psychiatric evaluation tools is improving diagnostic accuracy.

These technologies also support earlier intervention and improved patient monitoring.

Growth of Epidemiological Research

Large-scale patient registries, population health databases, and longitudinal studies are strengthening understanding of schizophrenia prevalence, incidence, and disease progression.

Improved epidemiological data support healthcare planning and therapeutic development.

Increasing Investment in Precision Psychiatry

Research into genetics, biomarkers, and personalized medicine is improving patient stratification and supporting more individualized treatment strategies.

Precision psychiatry is expected to enhance future epidemiological analyses and clinical outcomes.

Market Restraints

Underdiagnosis and Delayed Diagnosis

Many individuals remain undiagnosed because of social stigma, limited access to psychiatric care, or delayed recognition of early symptoms.

Late diagnosis may affect epidemiological accuracy and treatment outcomes.

Regional Differences in Healthcare Access

Availability of psychiatric specialists, diagnostic services, and mental healthcare infrastructure varies considerably across countries.

These disparities contribute to differences in reported prevalence and diagnosis rates.

Limited Epidemiological Data in Developing Regions

Several low- and middle-income countries continue to have limited mental health surveillance systems and incomplete patient registries.

Insufficient data may underestimate the true global disease burden.

Technology and Segment Insights

By Disease Severity

Patients are commonly categorized according to mild, moderate, and severe disease based on symptom intensity, functional impairment, and healthcare requirements.

Severe schizophrenia accounts for the greatest healthcare utilization due to frequent hospitalization and long-term psychiatric care.

By Age Group

Schizophrenia most commonly develops during late adolescence and early adulthood, although diagnosis may occur later depending on symptom progression and healthcare access.

Adult patients continue to represent the largest proportion of the diagnosed population.

By Gender

Schizophrenia affects both males and females, although males generally experience earlier disease onset and may present with more severe symptoms during early adulthood.

Females often demonstrate later onset and different clinical progression patterns.

By Healthcare Setting

Specialized psychiatric hospitals and mental health clinics account for the majority of confirmed diagnoses.

Community mental health centers, outpatient psychiatric services, and telepsychiatry platforms are becoming increasingly important for long-term patient management and epidemiological monitoring.

Regional Insights

North America represents one of the largest diagnosed schizophrenia populations owing to advanced mental healthcare infrastructure, widespread access to psychiatric services, comprehensive epidemiological surveillance, and strong investment in mental health research. The region benefits from well-established diagnostic guidelines and increasing adoption of digital mental health technologies.

Europe maintains a substantial diagnosed patient population supported by universal healthcare systems, strong psychiatric care networks, comprehensive disease registries, and collaborative research initiatives. Countries including Germany, the United Kingdom, France, Italy, and Spain continue investing in community-based mental healthcare and epidemiological monitoring.

Asia Pacific is expected to experience the fastest growth in diagnosed schizophrenia patients during the forecast period owing to expanding healthcare infrastructure, increasing mental health awareness, improved psychiatric services, rising healthcare expenditure, and government initiatives supporting mental healthcare across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually strengthening schizophrenia diagnosis and surveillance through healthcare modernization, expanded psychiatric services, increased awareness programs, and greater investment in mental health infrastructure.

Competitive and Strategic Outlook

The schizophrenia epidemiology landscape is increasingly supported by collaboration among healthcare providers, pharmaceutical companies, academic institutions, public health organizations, and digital health technology providers. Accurate epidemiological data are becoming increasingly valuable for clinical trial planning, healthcare resource allocation, commercial forecasting, reimbursement strategy, and market access planning.

Organizations continue investing in digital patient registries, artificial intelligence-assisted diagnostics, electronic health records, predictive analytics, and real-world evidence platforms to improve disease surveillance and patient identification. Strategic partnerships among governments, healthcare systems, and industry participants are expected to further strengthen epidemiological research and improve understanding of schizophrenia across diverse populations.

Conclusion

The global schizophrenia epidemiology landscape is expected to continue expanding as advances in psychiatric diagnostics, increasing mental health awareness, improved healthcare access, and stronger epidemiological surveillance enhance disease identification worldwide. Growing investment in precision psychiatry, digital health technologies, and patient registry development is expected to improve the accuracy of epidemiological assessments and support more effective healthcare planning. Although underdiagnosis, regional disparities, and persistent social stigma remain significant challenges, continued progress in mental healthcare infrastructure and research is expected to strengthen disease monitoring and improve long-term patient outcomes.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of schizophrenia prevalence, incidence, diagnosed patient population, demographic trends, and regional epidemiology.
• Strategic Planning Support: Understand disease burden to optimize clinical development, commercialization, and healthcare planning.
• Market Drivers and Future Trends: Assess factors influencing diagnosis rates, patient growth, and epidemiological trends.
• Actionable Recommendations: Support investment decisions, epidemiological forecasting, and healthcare resource allocation.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, research organizations, consultants, investors, and policymakers.

What Businesses Use Our Reports For

Epidemiological assessment, patient population forecasting, clinical trial planning, market opportunity analysis, healthcare resource allocation, commercial strategy development, regulatory planning, investment evaluation, and competitive intelligence.

Report Coverage

• Historical epidemiological analysis from 2021 to 2024, Base year 2025, and Forecast period from 2026 to 2035
• Global prevalence, incidence, diagnosed and undiagnosed patient population analysis
• Segmentation by disease severity, age group, gender, healthcare setting, and region
• Regional epidemiological trends, diagnosis patterns, healthcare access, and future patient forecasts
• Analysis of epidemiological drivers, unmet needs, and future growth opportunities

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Schizophrenia Epidemiology Overview
• 1.3 Global Disease Burden Snapshot (2025)
• 1.4 Key Epidemiological Insights
• 1.5 Major Trends Shaping the Schizophrenia Landscape
• 1.6 Forecast Highlights (2025-2045)
• 1.7 Strategic Implications for Stakeholders

2. Introduction to Schizophrenia

• 2.1 Disease Overview
  • 2.1.1 Definition and Clinical Characteristics
  • 2.1.2 Diagnostic Criteria
  • 2.1.3 Disease Classification
  • 2.1.4 Positive Symptoms
  • 2.1.5 Negative Symptoms
  • 2.1.6 Cognitive Impairment
  • 2.1.7 Functional Disability Burden
• 2.2 Etiology and Risk Factors
  • 2.2.1 Genetic Predisposition
  • 2.2.2 Neurodevelopmental Factors
  • 2.2.3 Neurochemical Abnormalities
  • 2.2.4 Environmental Risk Factors
  • 2.2.5 Substance Use and Schizophrenia Risk
  • 2.2.6 Urbanization and Socioeconomic Influences
• 2.3 Disease Pathophysiology
  • 2.3.1 Dopamine Dysregulation
  • 2.3.2 Glutamatergic Dysfunction
  • 2.3.3 GABAergic Pathways
  • 2.3.4 Neuroinflammation and Immune Mechanisms
  • 2.3.5 Synaptic Plasticity Alterations
• 2.4 Disease Burden and Healthcare Impact
  • 2.4.1 Disability Burden
  • 2.4.2 Mortality and Life Expectancy
  • 2.4.3 Quality-of-Life Impact
  • 2.4.4 Economic Burden
  • 2.4.5 Caregiver Burden

3. Epidemiology Methodology and Forecast Framework

• 3.1 Epidemiological Model Structure
• 3.2 Data Sources and Validation Framework
• 3.3 Population Modeling Assumptions
• 3.4 Forecast Methodology (2025-2045)
• 3.5 Disease Definition and Case Identification Criteria
• 3.6 Diagnostic Rate Assessment Framework
• 3.7 Treatment Penetration Assessment Framework
• 3.8 Sensitivity and Scenario Analysis

4. Global Schizophrenia Epidemiology Overview

• 4.1 Global Prevalent Cases
  • 4.1.1 Historical Trend Analysis (2015-2024)
  • 4.1.2 Forecast Analysis (2025-2045)
• 4.2 Global Incident Cases
  • 4.2.1 Historical Incidence Trends
  • 4.2.2 Forecast Incidence Trends
• 4.3 Diagnosed Patient Population
  • 4.3.1 Diagnosed Prevalent Cases
  • 4.3.2 Undiagnosed Patient Population
• 4.4 Treated Patient Population
  • 4.4.1 Treated Cases by Therapy Type
  • 4.4.2 Untreated Disease Burden
• 4.5 Disease Burden by Age Group
  • 4.5.1 Pediatric and Adolescent Population
  • 4.5.2 Young Adult Population
  • 4.5.3 Adult Population
  • 4.5.4 Elderly Population
• 4.6 Disease Burden by Gender
  • 4.6.1 Male Population
  • 4.6.2 Female Population
• 4.7 Disease Burden by Severity
  • 4.7.1 Mild Disease
  • 4.7.2 Moderate Disease
  • 4.7.3 Severe Disease

5. Epidemiology by Disease Stage and Clinical Characteristics

• 5.1 First-Episode Schizophrenia
• 5.2 Early-Onset Schizophrenia
• 5.3 Chronic Schizophrenia
• 5.4 Treatment-Resistant Schizophrenia
• 5.5 Relapsed Schizophrenia
• 5.6 Negative Symptom Predominant Population
• 5.7 Cognitive Impairment Population
• 5.8 Comorbidity Burden Assessment

6. Epidemiology by Healthcare Access and Treatment Status

• 6.1 Diagnosed vs Undiagnosed Population
• 6.2 Treated vs Untreated Population
• 6.3 Access to Psychiatric Care
• 6.4 Access to Antipsychotic Therapy
• 6.5 Access to Long-Acting Injectable Therapies
• 6.6 Mental Health Infrastructure Impact
• 6.7 Reimbursement and Coverage Impact on Diagnosis

7. Epidemiological Trends and Disease Drivers

• 7.1 Population Growth Impact
• 7.2 Aging Population Impact
• 7.3 Urbanization Trends
• 7.4 Mental Health Awareness Initiatives
• 7.5 Healthcare Infrastructure Expansion
• 7.6 Diagnostic Improvements
• 7.7 Socioeconomic Determinants
• 7.8 Digital Mental Health Integration
• 7.9 Early Intervention Programs Impact
• 7.10 Public Health Policy Influence

8. Forecast Analysis and Epidemiological Projections (2025-2045)

• 8.1 Global Epidemiological Forecast
  • 8.1.1 Total Prevalent Cases Forecast
  • 8.1.2 Total Incident Cases Forecast
  • 8.1.3 Diagnosed Cases Forecast
  • 8.1.4 Treated Cases Forecast
• 8.2 Forecast by Age Group
• 8.3 Forecast by Gender
• 8.4 Forecast by Disease Severity
• 8.5 Forecast by Disease Stage
• 8.6 Forecast by Treatment Status
• 8.7 Forecast Under Alternative Scenarios
  • 8.7.1 Conservative Scenario
  • 8.7.2 Base Case Scenario
  • 8.7.3 Optimistic Scenario

9. Geographic Analysis (Regional Level Only)

• 9.1 North America
  • 9.1.1 Epidemiology Overview
  • 9.1.2 Prevalence Analysis
  • 9.1.3 Incidence Analysis
  • 9.1.4 Diagnosed Population
  • 9.1.5 Treated Population
  • 9.1.6 Key Regional Drivers
  • 9.1.7 Forecast Outlook
• 9.2 Europe
  • 9.2.1 Epidemiology Overview
  • 9.2.2 Prevalence Analysis
  • 9.2.3 Incidence Analysis
  • 9.2.4 Diagnosed Population
  • 9.2.5 Treated Population
  • 9.2.6 Key Regional Drivers
  • 9.2.7 Forecast Outlook
• 9.3 Asia-Pacific
  • 9.3.1 Epidemiology Overview
  • 9.3.2 Prevalence Analysis
  • 9.3.3 Incidence Analysis
  • 9.3.4 Diagnosed Population
  • 9.3.5 Treated Population
  • 9.3.6 Key Regional Drivers
  • 9.3.7 Forecast Outlook
• 9.4 Latin America
  • 9.4.1 Epidemiology Overview
  • 9.4.2 Prevalence Analysis
  • 9.4.3 Incidence Analysis
  • 9.4.4 Diagnosed Population
  • 9.4.5 Treated Population
  • 9.4.6 Key Regional Drivers
  • 9.4.7 Forecast Outlook
• 9.5 Middle East & Africa
  • 9.5.1 Epidemiology Overview
  • 9.5.2 Prevalence Analysis
  • 9.5.3 Incidence Analysis
  • 9.5.4 Diagnosed Population
  • 9.5.5 Treated Population
  • 9.5.6 Key Regional Drivers
  • 9.5.7 Forecast Outlook

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Prevalence Analysis
  • 10.1.2 Incidence Analysis
  • 10.1.3 Diagnosed Population
  • 10.1.4 Treated Population
  • 10.1.5 Forecast Outlook
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Comparative Epidemiology Assessment

• 11.1 Regional Burden Comparison
• 11.2 Country-Level Disease Burden Comparison
• 11.3 Incidence Rate Comparison
• 11.4 Prevalence Rate Comparison
• 11.5 Diagnosis Gap Comparison
• 11.6 Treatment Gap Comparison
• 11.7 Healthcare Access Comparison
• 11.8 Forecast Growth Comparison
• 11.9 High-Burden Country Ranking
• 11.10 Emerging Growth Markets

12. Healthcare System and Policy Landscape

• 12.1 Global Mental Health Policies
• 12.2 National Schizophrenia Management Frameworks
• 12.3 Screening and Early Detection Initiatives
• 12.4 Access-to-Care Programs
• 12.5 Reimbursement Environment
• 12.6 Mental Health Funding Trends
• 12.7 Public Awareness Programs
• 12.8 Future Policy Developments

13. Future Outlook and Strategic Insights

• 13.1 Key Epidemiological Shifts Through 2045
• 13.2 Emerging Population Hotspots
• 13.3 Diagnosis Rate Evolution
• 13.4 Treatment Penetration Evolution
• 13.5 Impact of Mental Health Policy Expansion
• 13.6 Impact of Digital Psychiatry Adoption
• 13.7 Long-Term Disease Burden Outlook
• 13.8 Strategic Opportunities for Stakeholders
• 13.9 Key Risks and Uncertainties

14. Appendix

• 14.1 Abbreviations
• 14.2 Epidemiology Definitions
• 14.3 Data Sources
• 14.4 Forecast Assumptions
• 14.5 Statistical Methodology
• 14.6 Glossary of Terms
• 14.7 References
• 14.8 Disclaimer